1. Risk & Prognosis

    Comments Leave a Comment

    1-5 of 5
    1. Mentioned In 5 Articles

    2. Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

      Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Aug 24; Authors: Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL
      Read Full Article
    3. Incidence, Trends, and Survival of Children With Embryonal Tumors.

      Incidence, Trends, and Survival of Children With Embryonal Tumors. Pediatrics. 2015 Aug 24; Authors: Tulla M, Berthold F, Graf N, Rutkowski S, von Schweinitz D, Spix C, Kaatsch P Abstract BACKGROUND: Central nervous system (CNS) and non-CNS embryonal tumors occur principally in children and are rarely seen in adults. The incidence rates for rare entities such as atypical teratoid/rhabdoid tumors (AT/RT) or primitive neuroectodermal tumors in the CNS ...
      Read Full Article
    4. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.

      Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.
      Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors. Cell Death Dis. 2014;5:e1100 Authors: Veschi V, Petroni M, Bartolazzi A, Altavista P, Dominici C, Capalbo C, Boldrini R, Castellano A, McDowell HP, Pizer B, Frati L, Screpanti I, Gulino A, Giannini G
      Read Full Article
      Mentions: Risk & Prognosis
    5. Mechanisms of neuroblastoma regression.

      Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol. 2014 Oct 21; Authors: Brodeur GM, Bagatell R Abstract Recent genomic and biological studies of neuroblastoma have shed light on the dramatic heterogeneity in the clinical behaviour of this disease, which spans from spontaneous regression or differentiation in some patients, to relentless disease progression in others, despite intensive multimodality therapy.
      Read Full Article
      Mentions: Risk & Prognosis
    6. Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma.

      Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma. Pediatr Res. 2014 Feb;75(2):302-14 Authors: Tadeo I, Piqueras M, Montaner D, Villamn E, Berbegall AP, Caete A, Navarro S, Noguera R
      Read Full Article
    7. 1-5 of 5
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video